Biocon Limited has informed the Exchange about Investor Presentation
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon submitted its May 2025 corporate presentation to the exchanges under Regulation 30. The deck outlines the group's structure across Biosimilars (58% of FY25 revenue), Generics (19%), and Research Services/Syngene (23%). FY25 group revenue rose to USD 1,806 mn from USD 1,322 mn in FY23, with EBITDA at USD 518 mn (27% margin). Five biosimilars are slated for near-term launch, and the company highlights its early-mover position in generic GLP-1 peptides (Liraglutide already approved in UK). R&D spend in FY25 was USD 137 mn, about 9% of biologics revenue. Gross debt stood at USD 2,101 mn (net leverage 2.9x), with management explicitly stating deleveraging as a continued objective.
Shares detailed business pipeline and deleveraging roadmap, reinforcing growth narrative around biosimilars and GLP-1 peptides. For investors, the explicit commitment to debt reduction and visibility on 5 near-term biosimilar launches are positive signals, though margins have compressed from 37% (FY23) to 27% (FY25).